

1 **Higher ratio of plasma omega-6/omega-3 fatty acids is associated**
2 **with greater risk of all-cause, cancer, and cardiovascular mortality:**
3 **a population-based cohort study in UK Biobank**

4

5

6 **Authors:** Yuchen Zhang, MSPH¹; Yitang Sun, MPH²; Qi Yu, MSPH³, Suhang Song, PhD⁴, J.
7 Thomas Brenna, PhD^{5,6}; Ye Shen, PhD^{1*}; Kaixiong Ye, PhD^{2,7*}

8

9 **Author Affiliations:**

10 ¹ Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia,
11 Athens, Georgia, US

12 ² Department of Genetics, University of Georgia, Athens, Georgia, US

13 ³ Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, US

14 ⁴ Department of Health Policy and Management, College of Public Health, University of Georgia,
15 Athens, Georgia, US

16 ⁵ Division of Nutritional Sciences, Cornell University, Ithaca, NY, US

17 ⁶ Dell Pediatric Research Institute and the Depts of Pediatrics, of Nutrition, and of Chemistry,
18 University of Texas at Austin, Austin, TX, US

19 ⁷ Institute of Bioinformatics, University of Georgia, Athens, Georgia, US

20 * YS and KY jointly supervised this project.

21

22 **Corresponding Author:**

23 Kaixiong Ye, PhD

24 Department of Genetics, C220 Davison Life Sciences Complex, University of Georgia, 120 East
25 Green Street, Athens, GA 30602

26 Phone: 706-542-5898 Email: kaixiong.ye@uga.edu

27

28 **Abstract**

29 **Background**

30 Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated
31 with various chronic diseases and mortality, but results are conflicting. Few studies examined the
32 role of a balanced omega-6/omega-3 ratio in mortality.

33 34 **Methods**

35 We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and
36 cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants
37 who had complete information on circulating PUFAs, 6,461 died during follow-up, including
38 2,794 from cancer and 1,668 from cardiovascular disease (CVD). Associations were estimated
39 by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.

40 41 **Results**

42 Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs
43 increased (all $P_{\text{trend}} < 0.05$). Comparing the highest to the lowest quintiles, individuals had 26%
44 (95% CI, 15-38%) higher total mortality, 14% (95% CI, 0-31%) higher cancer mortality, and 31%
45 (95% CI, 10-55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma
46 were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing
47 stronger effects.

48 49 **Conclusions**

50 Using a population-based cohort in UK Biobank, our study revealed a strong association between
51 the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD
52 mortality.

53 54 **Keywords**

55 Polyunsaturated fatty acids, Omega-3 fatty acids, Omega-6 fatty acids, Mortality, Prospective
56 studies

57

58 **Background**

59
60 Cancer and cardiovascular disease (CVD) are the two leading causes of non-communicable
61 disease mortality globally¹. Substantial epidemiologic evidence has linked the dietary or
62 circulating levels of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) to the risks of
63 all-cause, cancer, and CVD mortality (**Additional file 1: Table S1**). However, the results are
64 inconsistent, especially for omega-6 PUFAs. Most large observational studies support the
65 protective effects of omega-3 PUFAs. In addition to total and individual omega-3 PUFAs, the
66 omega-3 index, defined as the percentage of eicosapentaenoic acid (EPA) and docosahexaenoic
67 acid (DHA) in total fatty acids in red blood cells, was shown to be a validated biomarker of the
68 dietary intake and tissue levels of long-chain omega-3 PUFAs, and was proposed to be a risk
69 factor for CVD and related mortality^{2,3}. While the omega-3 index has been observed to be
70 inversely associated with all cause-mortality, its association patterns with CVD and cancer
71 mortality are less clear⁴⁻⁶. Most importantly, results from clinical trials of omega-3 PUFA
72 supplementation have been inconsistent^{7,8}. On the other hand, while some studies revealed
73 inverse associations of omega-6 PUFAs with all-cause mortality⁹⁻¹¹, others reported null
74 results^{4,12-15}. The role of omega-6 PUFAs in cancer and CVD mortality is less studied, and the
75 patterns are similarly conflicting^{4,9-11}. Interpreting previous observational results is challenging
76 due to the limitations of small sample sizes, insufficient adjustments for confounding, and unique
77 sample characteristics. Moreover, many studies rely on self-reported dietary intake or fish oil
78 supplementation status, which are subject to large variability and reporting bias¹⁶. Despite the
79 tremendous interest and research effort, the roles of omega-3 and omega-6 PUFAs in all-cause
80 and cause-specific mortality remain controversial.

81

82 It has been suggested that the high omega-6/omega-3 ratio in Western diets, 20:1 or even higher,
83 as compared to an estimated 1:1 during the most time of human evolution, contributes to many
84 chronic diseases, including CVD, cancer, and autoimmune disorders^{17,18}. However, while many
85 previous studies have examined total or individual omega-3 and omega-6 PUFAs, fewer
86 investigated the role of their imbalance, as measured by the omega-6/omega-3 ratio, in
87 mortality^{4,14,15,19}. In a prospective cohort study of postmenopausal women, the omega-6/omega-3
88 ratio in red blood cells was associated with an increased risk of all-cause mortality but not with
89 cancer or CVD mortality⁴. Similar positive associations with all-cause mortality were observed
90 in smaller cohorts investigating the ratio in serum or dietary intake^{14,19}. However, prospective
91 studies in two independent cohorts from China and US did not find a linear positive association
92 between the omega-6/omega-3 ratio in diet and all-cause mortality¹⁵. To address these gaps in
93 our understanding of the roles of omega-3 and omega-6 PUFAs and their imbalance in all-cause
94 and cause-specific mortality, we perform a prospective study in a large population-based cohort
95 (N = 85,425) from UK Biobank, using objective measurements of PUFA levels in plasma.

96

97 **Methods**

98 *Study population*

99 The UK Biobank study is a prospective, population-based cohort study in the United Kingdom²⁰.
100 Between 2006 and 2010, 502,384 prospective participants, aged 40-69, in 22 assessment Centers
101 throughout the UK were recruited for the study. The population information was collected
102 through a self-completed touch-screen questionnaire; brief computer-assistant interview;
103 physical and functional measures; and blood, urine, and saliva collection during the assessment
104 visit. Participants with cancer (n=37,736) or CVD (n=100,972), those who withdrew from the

105 study (n=879), and those with incomplete data on the plasma omega-6/omega-3 ratio (n=277,372)
106 were excluded from this study, leaving 85,425 participants, 6,461 died during follow-up,
107 including 2,794 from cancer and 1,668 from CVD.

108

109 *Ascertainment of exposure*

110 Plasma PUFA levels (absolute concentrations and percentages of total fatty acids) were
111 measured by nuclear magnetic resonance (NMR) in plasma samples collected between 2007 and
112 2010, including total PUFAs, omega-3 PUFAs, omega-6 PUFAs, docosahexaenoic acid (DHA),
113 and linoleic acid (LA)²⁰⁻²².

114

115 *Ascertainment of outcome*

116 The date and cause of death were identified through the death registries of the National Health
117 Service (NHS) Information Centre for participants from England and Wales and the NHS Centre
118 Register Scotland for participants from Scotland²⁰. At the time of the analysis (15 Mar 2023), we
119 had access to the most up-to-date mortality dataset (Version: December 2022), which had the
120 date of death up to 12 November 2021. Therefore, follow-up time was calculated as the time
121 between the date of entering the assessment centre and this date, or the date of death, whichever
122 happened first. The underlying cause of death was assigned and coded in vital registries
123 according to the International Classification of Diseases, 10th revision (ICD-10). CVD mortality
124 was defined using codes I00-I99, and cancer mortality was defined using codes C00-D48. To
125 exclude those who had cancer at baseline, we used the overall cancer incidence information
126 based on diagnoses in cancer registers derived from the Health and Social Care Information
127 Centre and the NHS Central Register that were coded based on ICD-9 and ICD-10 codes. The

128 information about CVD incidence was retrieved from Hospital inpatient data and Death Register
129 records that were coded according to ICD-9 and ICD-10 codes, and self-reported medical
130 condition.

131

132 *Ascertainment of covariates*

133 The baseline questionnaire included detailed information on several possible confounding
134 variables: demographic factors (age, sex, assessment centre, ethnicity), socioeconomic status
135 (Townsend Deprivation Index), lifestyle habits (alcohol assumption, smoking status, body mass
136 index (BMI), physical activity, comorbidities (including hypertension, diabetes, and
137 longstanding illness)), and other supplementation (Fish-oil supplementation). The Townsend
138 Deprivation Index, used as an indicator of socioeconomic status, is retrieved directly from the
139 UK Biobank. BMI was defined as the body mass divided by the square of the body height and
140 was expressed in units of kg/m^2 . Prevalent hypertension was derived from a self-reported history
141 of hypertension. Information on diabetes and longstanding illness was collected by self-report at
142 baseline. We also retrieved the information on dietary PUFA intakes and serum biomarkers for
143 secondary analysis. Dietary PUFAs were estimated based on the 24-hour dietary recall²³. The
144 percentage of dietary omega-3 and omega-6 PUFA were calculated as the corresponding
145 absolute dietary PUFA divided by summation of dietary monounsaturated fatty acids, saturated
146 fatty acids, omega-3 fatty acids, and omega-6 fatty acids. The biochemistry markers were
147 measured in the blood sample collected at recruitment.

148

149

150

151

152 *Statistical analysis*

153 We summarized and compared the characteristics of the participants across quintiles of the
154 omega-6/omega-3 ratio at baseline using descriptive statistics. Pearson's Chi-squared test and
155 ANOVA test were used to compare the demographic characteristics across quintiles, respectively,
156 for categorical variables and continuous variables. To investigate associations of the ratio with
157 all-cause and cause-specific mortality, we used multivariable Cox proportional hazards
158 regression models to calculate hazard ratios²⁴ and their 95% confidence intervals (CI). The
159 proportional hazards assumption was not violated based on Schoenfeld residuals. We analyzed
160 the ratio as continuous and categorical variables (i.e., quintiles). For all trend tests, we used the
161 median value of each quintile as a continuous variable in the models. Potential nonlinear
162 associations were assessed semi-parametrically using restricted cubic splines (4 knots were used
163 in regression splines)²⁵.

164

165 Based on previous literature and biological plausibility^{11,26,27}, we chose the following variables
166 as covariates in the multivariate models: age (years; continuous), sex (male, female), race (White,
167 Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI
168 (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never,
169 previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

170

171 In secondary analyses to assess potential differences in associations across different population
172 subgroups, we repeated the above-described analyses stratified by age (< vs. ≥ the median age of
173 58 years), sex (male/female), Townsend deprivation index (< vs. ≥ the population median of -2),

174 BMI ($< vs. \geq 25$), comorbidities (yes vs. no), physical activity (low and moderate vs. high) and
175 current smoking status (yes vs. no). Besides, to compare the effects of dietary intake of PUFAs
176 with the plasma levels on mortality, we repeated the above-described analyses in participants
177 with complete information on dietary intake PUFAs (N=153,064). Moreover, we conducted
178 mediation analysis to investigate potential biological pathways that might explain the effects of
179 omega-6/omega-3 ratio on mortality outcomes. Based on plausibility, we chose Cholesterol,
180 LDL, HDL-C, TG, ApoA, ApoB, CRP and Lp(a) as potential mediating factors for CVD
181 mortality; SHBG, TTST, E2 and IGF-1 as potential mediating factors for cancer mortality; and
182 all the above biomarkers for all-cause mortality. We first examined the variations in the
183 concentrations of each biomarker according to omega-6/omega-3 ratio quintiles. Then we
184 constructed two regression models, a linear model, to regress the mediator (treated the
185 biomarkers as continuous) on the exposure (treated the omega-6/omega-3 ratio as continuous),
186 with fully-adjustment for potential confounders; and a Cox proportional hazard model, to regress
187 the outcome (mortality outcomes) on the exposure and the mediator, with fully-adjustment for
188 potential confounders. We chose to construct Cox models for mediation analysis because our
189 outcomes were rare (all $<10\%$)²⁸. We integrated these two regression models to obtain the
190 indirect effects and proportions of mediating effects through the counterfactual-based approach
191 proposed by Vander Weele^{29,30}.

192
193 We also conducted several sensitivity analyses. First, to assess whether the associations of the
194 omega-6/omega-3 ratio with mortality outcomes were primarily driven by omega-3 fatty acids or
195 omega-6 fatty acids, we assessed both the separate and the joint associations of omega-3 fatty
196 acids to total fatty acids percentage (omega-3%) and omega-6 fatty acids to total fatty acids

197 percentage (omega-6%) with the three mortality outcomes. We also performed a joint analysis
198 with categories of the omega-3% and omega-6% quintiles, using participants in both the lowest
199 omega-3% and omega-6% quintiles as the reference category. An interaction term between
200 omega-3% and omega-6% was included in the multivariable Cox proportional hazards model,
201 and a Likelihood Ratio test was used to assess its significance. The correlation between omega-3%
202 and omega-6% was assessed by the Pearson correlation. Second, to assess the effects of
203 individual PUFAs on mortality, we conducted the same analysis for circulating docosahexaenoic
204 acid to total fatty acids percentage (DHA%) and linoleic acid to total fatty acids percentage
205 (LA%) with the three mortality outcomes. Third, to address the potential residual confounding
206 by fish oil supplementation, we further adjusted for the supplementation status from the baseline
207 questionnaire. Fourth, to investigate the effects of missing values, we imputed missing values
208 (<1% for most factors, up to 19% for physical activity) by chained equations and performed
209 synthesis analyses on the imputed datasets³¹. Fifth, to assess whether the observed associations
210 are attenuated by reverse causation, we excluded those who died in the first year of follow-up.
211 Last, to assess the representativeness of the participants included in our study, we compared the
212 baseline characteristics between the participants with and without exposure information. All P-
213 values were two-sided. We considered a P-value <0.05 or a 95% confidence interval (CI)
214 excluding 1.0 for HRs as statistically significant. We conducted all analyses using R, version
215 4.0.3 and SAS statistical software, version 9.4 (SAS Institute Inc.).

216

217

218

219

220

221

222 **Results**

223 *Baseline characteristics*

224 In the analytic cohort of 85,425 participants, over a mean of 12.7 years of follow-up, 6,461 died,
225 including 2,794 from cancer and 1,668 from CVD. The baseline characteristics of the
226 participants across quintiles of the ratio of omega-6/omega-3 were summarized in **Table 1**. Study
227 participants were, on average, 56 years old and 90% White. Those in the higher ratio quintiles
228 were more likely to be younger, male, and current smokers, but less likely to have comorbidities
229 and take fish oil supplementation.

230

231 *Main results*

232 The associations of the omega-6/omega-3 ratio with all-cause and cause-specific mortality risks
233 were presented in **Table 2**. A higher ratio was strongly associated with higher mortality from all
234 causes, cancer, and CVD ($P_{\text{trend}} < 0.05$ for all three). In the fully adjusted models that considered
235 the ratio as a continuous variable, every unit increase in the ratio corresponded to 2%, 1%, and 2%
236 higher risk in all-cause, cancer, and CVD mortality, respectively. When comparisons were made
237 between the highest and the lowest quintile of the omega-6/omega-3 ratio, there were 26%, 14%,
238 and 31% increased risk for all-cause, cancer, and CVD mortality, respectively.

239

240 *Stratified analysis*

241 The fully adjusted associations of the omega-6/omega-3 ratio with all-cause mortality revealed
242 that compared to the lowest quintile, the highest quintile has strong, statistically significant

243 associations with elevated risk within all categories of age, sex, TDI, BMI, comorbidities,
244 physical activity, and smoking status (**Figure 1, Additional file 2: Table S2**), except in those
245 aged less than 58 years old and BMI less than 25. The estimated associations with all-cause
246 mortality were stronger in current smokers (P for interaction < 0.01; **Figure 1, Additional file 2:
247 Table S2**). For cancer and CVD mortality, they also tended to be stronger among current
248 smokers but did not reach statistical significance (P for interaction = 0.13 and 0.12, respectively).
249 The associations with CVD mortality tended to be stronger among participants without
250 comorbidities (P for interaction <0.01). No significant interactions were found for other risk
251 factors (**Figure 2**).

252

253 *Restricted cubic spline analysis*

254 Restricted cubic spline analysis suggested significant positive associations of the omega-
255 6/omega-3 ratio with all-cause, cancer, and CVD mortality (P < 0.05 for all three outcomes,
256 **Figure 3**). Potential nonlinearity in these positive associations was identified for all-cause
257 mortality (P < 0.05) and CVD mortality (P < 0.05) but not for cancer mortality (P = 0.12). The
258 strength of the relationship between the ratio and all-cause mortality appears to remain at a
259 relatively low level before it starts to increase quickly after the ratio exceeds 8. A similar trend
260 with higher uncertainties was observed for CVD mortality.

261

262 *Omega-3, Omega-6, Joint analysis, and comparison with dietary PUFAs*

263 We further performed analyses to assess whether the associations of the omega-6/omega-3 ratio
264 with mortality outcomes were primarily driven by omega-3 or omega-6 fatty acids. The
265 correlation between omega-3% and omega-6% was relatively low with $r = -0.12$ (P < 0.01).

266 Across all models, both the omega-3% and omega-6% were inversely associated with all three
267 mortality outcomes, except for plasma omega-6% with CVD mortality under Model 3 ($P_{\text{trend}} <$
268 0.01, **Additional file 2: Table S3 and Table S4**). Notably, their associations remained
269 significant when they were included in the same models. On the other hand, the effect sizes of
270 the inverse associations were always bigger for the omega-3% under the fully adjusted Model 3.
271 For example, when comparing those in the highest omega-3% quintile to the lowest quintile, the
272 fully adjusted HRs (95% CI) for all-cause, cancer, and CVD mortality were, respectively, 0.69
273 (0.63, 0.76), 0.75 (0.65, 0.87), and 0.68 (0.57, 0.82) (**Additional file 2: Table S3**). The
274 corresponding HRs for the omega-6% were 0.77 (0.70, 0.85), 0.80 (0.68, 0.92), and 0.83 (0.68,
275 1.02) (**Additional file 2: Table S4**). Furthermore, in another joint analysis of the omega-3% and
276 omega-6%, the lowest risk for all-cause and cancer mortality was observed among those in the
277 joint highest categories of the two fatty acids (**Additional file 2: Table S5**). For example, when
278 comparing those in the highest quintiles of the two fatty acids to the group with the joint lowest
279 group, the HRs (95% CI) for all-cause and cancer mortality were, respectively, 0.48 (95% CI,
280 0.35, 0.67) and 0.53 (95% CI, 0.33, 0.86). In the analysis of dietary PUFAs with mortality, the
281 effect sizes were smaller and less significant compared with those of the corresponding plasma
282 levels. When analyzed as continuous variables, dietary omega-3%, omega-6% and omega-
283 6/omega-3 ratio were all significantly associated with all-cause, cancer, and CVD mortality, in
284 directions consistent with their plasma counterparts. The trend test across the five quintiles
285 revealed significant associations between dietary omega-3% and omega-6/omega-3 ratio with
286 cancer mortality (P for trend < 0.001 and $= 0.002$, respectively; **Additional file 2: Table S6**). The
287 correlation between dietary omega-3% and omega-6% was $r = 0.41$ ($P < 0.01$).
288

289 ***Mediation analysis for intermediate biomarkers***

290 The baseline serum biomarkers of the participants across quintiles of the ratio of omega-
291 6/omega-3 were summarized in **Additional file 2: Table S7**. The estimates for the three paths a
292 (association between plasma omega-6/omega-3 ratio and biomarkers), b (association between
293 biomarkers and mortality outcomes), and c (association between plasma omega-6/omega-3 ratio
294 and mortality outcomes), as well as the percentage of indirect effect (a to b) among the overall
295 associations, were reported in **Additional file 2: Table S8 and Figure S1**. These analyses
296 identified cholesterol, LDL, ApoB, and SHBG as potential mediators for the association of
297 plasma omega-6/omega-3 ratio with all-cause mortality (proportion of mediating = 14.7%,
298 10.8%, 11.0%, and 5.0%, respectively); cholesterol, LDL, ApoA and ApoB as potential
299 mediators for CVD mortality (proportion of mediating = 16.7%, 11.0%, 6.5%, and 9.8%,
300 respectively).

301

302 ***Other sensitivity analyses***

303 We performed analyses to examine the associations of DHA% and LA% with mortalities. The
304 correlation between DHA% and LA% was relatively low with $r = 0.03$ ($P < 0.01$). Under the
305 fully-adjusted model, both DHA% and LA% were inversely associated with all three mortality
306 outcomes, regardless of treated as continuous or quintiles (**Additional file 2: Table S9**). After
307 further adjustment of the fish oil supplementation status, the associations between the ratio of
308 omega-6/omega-3 and mortality outcomes were slightly attenuated yet did not alter the main
309 findings (**Additional file 2: Table S10**). Our primary analysis excluded participants with
310 missing information (i.e., a complete-case analysis). We performed a sensitivity analysis using
311 the multiply-imputed datasets, and there were no substantial changes (**Additional file 2: Table**

312 **S11**). Moreover, the exclusion of participants who died during their first-year follow-up did not
313 materially alter the results (**Additional file 2: Table S12**). The baseline characteristics are
314 comparable between participants with or without exposure information (**Additional file 2: Table**
315 **S13**).

316 **Discussion**

317 In this prospective population-based study of UK individuals, we showed that a higher ratio of
318 plasma omega-6/omega-3 fatty acids was positively associated with the risk of all-cause, cancer,
319 and CVD mortality. These associations were independent of most risk factors examined,
320 including age, sex, TDI, BMI, comorbidities, and physical activity, but they were stronger in
321 current smokers. These relationships were linear for cancer mortality but not for all-cause and
322 CVD mortality. For those two outcomes, the risk of mortality first decreased at lower ratios and
323 then increased, with an inflection point around the ratio of 8. Moreover, omega-3 and omega-6
324 PUFAs in plasma were consistently and inversely associated with all-cause, cancer, and CVD
325 mortality, with omega-3 showing stronger effects.

326
327 To date, studies that examined the relationship between the ratio of omega-6/omega-3 PUFAs
328 and mortality in the general population are sparse^{4,14,15,19}. Similar to our finding, in a 2017 report
329 from a prospective women cohort study (n=6,501; 1,875 all-cause deaths, 617 CVD deaths, 462
330 cancer deaths)⁴, the adjusted HR for all-cause mortality was 1.10 (1.02-1.19) per 1-SD increase
331 of omega-6/omega-3 ratio in red blood cells, however, the effects were not significant for cancer
332 and CVD deaths. Another study supporting our results was conducted on elderly Japanese
333 individuals (n=1,054; 422 deaths). It found that the ratio of an omega-3 fatty acid,
334 eicosapentaenoic acid, to an omega-6 fatty acid, arachidonic acid (ARA), is inversely associated

335 with all-cause mortality, with an HR of 0.71 (95% 0.53–0.96) comparing the highest to the
336 lowest tertile¹⁴. Findings of previous studies based on dietary intake were null^{15,19}. A prospective
337 cohort involving 145 hemodialysis patients enrolled in Southern California during 2001-2007
338 (42 all-cause deaths) showed that the estimated HR (95% CI) for all-cause mortality among those
339 in the lowest relative to the highest quartiles of dietary omega-6/omega-3 ratio was 0.37 (0.14-
340 1.08)¹⁹. Although the effect was not significant, it still shows the protective trend of a lower
341 omega-6/omega-3 ratio against premature death, when taking the sample size and study
342 population into consideration. In a 2019 report based on two population-based prospective
343 cohorts in China (n=14,117, 1,007 all-cause deaths) and the US (n=36,032, 4,826 all-cause
344 deaths), the effect of the omega-6/omega-3 ratio intake was not significant (HR (95% CI) is 0.95
345 (0.80-1.14) for China and 0.99 (0.89-1.11) for US, respectively)¹⁵. These discrepancies may be
346 explained by the usage of circulating biomarkers or dietary intakes for calculating the omega-
347 6/omega-3 ratio. Indeed, we performed the same association analyses for dietary PUFAs and
348 found that their associations with mortality have smaller effect sizes and are less statistically
349 significant, although maintaining the same effect directions as plasma PUFAs. The estimated
350 dietary intakes may be inaccurate due to recall bias or outdated food databases¹⁶. The circulating
351 level is a more objective measurement of PUFA status and thus provides a more reliable picture
352 of the effects of omega-3 and omega-6 PUFAs on mortality. Additionally, we observed that the
353 omega-6/omega-3 ratio tends to have stronger effects on mortality outcomes in current smokers.
354 This is consistent with a previous observation that the association between habitual fish oil
355 supplementation and a lower risk of all-cause mortality is stronger in current smokers²⁶.
356 Moreover, we found that current smokers in UK Biobank tend to have higher omega-6/omega-3
357 ratios. Similarly, prior studies reported that current smokers have lower circulating omega-3

358 PUFAs than non-smokers but similar circulating levels of omega-6 PUFAs^{32,33}. It is likely that
359 omega-3 PUFAs play more important roles in current smokers, resulting in a stronger effect of
360 the omega-6/omega-3 ratio on mortality. However, the underlying mechanism awaits future
361 investigations.

362

363 A large number of existing observational studies documented the inverse association of
364 circulating levels and intake of omega-3 PUFAs with mortality^{5,6,27,34-39}, which is in line with our
365 finding that individuals in the highest quintile of the plasma omega-3% had approximately 30%
366 lower risk for all-cause and CVD mortality and 25% lower risk for cancer mortality, when
367 compared to those in the lowest quintile. Our analysis of dietary omega-3% also revealed inverse
368 associations with all-cause and cancer mortality, with 9% and 18% lower risk, respectively. Few
369 previous studies have examined the association in generally healthy populations^{5,27,34,36}. In a
370 2016 meta-analysis³⁴ of seven epidemiologic studies for dietary omega-3 PUFAs intake and four
371 studies for circulating levels, the estimated relative risk for all-cause mortality was 0.91 (95% CI:
372 0.84-0.98) when comparing the highest to the lowest categories of omega-3 PUFA intake. In two
373 2018 reports of population-based studies in the US, the circulating level and dietary intake of
374 omega-3 PUFAs were significantly associated with lower total mortality^{5,27}. In a 2021 meta-
375 analysis of 17 epidemiologic studies, comparing the highest to the lowest quintiles of circulating
376 EPA and DHA, the estimated HRs for all-cause, CVD, and cancer mortality were 0.84 (0.79-
377 0.89), 0.80 (0.73-0.88) and 0.87 (0.78-0.96), respectively³⁶. Moreover, inverse associations of
378 omega-3 PUFAs biomarkers with total mortality were found in patients with myocardial
379 infarction^{37,39}, type 2 diabetes¹², and other diseases^{6,35,38,40}; inverse associations of omega-3
380 PUFAs with CVD mortality were also reported in these patient groups^{6,12,39}. However, there are

381 also reports of a null relationship between omega-3 PUFAs and mortality^{13,14,41}. One possible
382 explanation for the discrepancies could be the limited statistical power due to the small sample
383 size and the small number of events. Moreover, the inconsistency may be due to unique sample
384 characteristics; one study only involved elder patients¹⁴, and one only involved women⁴¹.

385
386 A smaller number of studies have evaluated the associations of omega-6 PUFAs with mortality.
387 Our findings in the large UK prospective cohort are in accordance with the results of several
388 previous studies that increased circulating levels of omega-6 PUFAs were associated with
389 decreased all-cause mortality^{9,11,15,42}. Moreover, a 2019 meta-analysis involving 18 cohort
390 studies and 12 case-control studies showed that an omega-6 PUFA, linoleic acid, was inversely
391 associated with CVD mortality; the HR per interquintile range was 0.78 (95% CI, 0.70-0.85)¹⁰.
392 Other studies, however, did not support such inverse associations^{4,12-14,41}. Although the findings
393 were inconsistent, no previous studies reported harmful effects of omega-6 PUFAs on
394 mortality^{4,11-15,41-44}. Our studies support the protective effects of omega-6 PUFAs on all-cause
395 and cause-specific mortality. Further research is needed to investigate the health impacts of
396 omega-6 PUFAs in laboratory studies, epidemiological investigations, and clinical trials.

397
398 We observed that the omega-6/omega-3 ratio is positively, while both of its numerator and
399 denominator, omega-6% and omega-3%, are negatively associated with mortality. Our findings
400 support that both omega-6 and omega-3 PUFAs are protective against death and that the positive
401 associations of the omega-6/omega-3 ratio with mortality outcomes are likely due to the stronger
402 effects of omega-3 than omega-6 PUFAs. Our mediation analysis with clinical biomarkers for
403 CVD and cancer revealed that cholesterol, LDL, and ApoB partially mediate the effects of the

404 omega-6/omega-3 ratio on all-cause and CVD mortality. However, the proportions mediated are
405 relatively small (~10%), suggesting the presence of direct effects or unexamined factors. Our
406 findings call for future studies that evaluate the utility and investigate the mechanisms of the
407 omega-6/omega-3 ratio.

408

409 Strengths of our current study include the use of objective PUFA biomarkers in plasma instead
410 of the estimated intakes from dietary questionnaires, which increases the accuracy of exposure
411 assessment. Moreover, the prospective population-based study design, large sample size, long
412 duration of follow-up, and detailed information on potential confounding variables, substantially
413 mitigate the possible complications from reverse causality and confounding bias. In several
414 sensitivity analyses, most of the documented associations remain materially unchanged,
415 indicating the robustness of our results.

416

417 Several potential limitations deserve attention. First, plasma omega-3 and omega-6 PUFAs were
418 measured only once at baseline. Their levels may vary with diet or other lifestyle factors, which
419 could cause misclassification over follow-up. However, some studies demonstrated that multiple
420 measurements of omega-3 PUFAs have been consistent for a 6-month period⁴⁵. Moreover, the
421 13-year within-person correlation for circulating omega-6 PUFAs was comparable to such
422 correlations for other major CVD risk factors⁴⁶. Thus, the single measurement of PUFAs at
423 baseline, although not perfect, provides us with adequate information to investigate the relative
424 long-term effects. Second, although we adjusted for many potential confounders in the model,
425 we cannot rule out the imprecisely measured and unmeasured factors. Last, although we included

426 individuals of different ancestries in the analysis, over 90% of the participants were of European
427 ancestry. The generalizability of our findings across ancestries requires future verification.

428

429

430

431

432 **Conclusions**

433 In this large prospective cohort study, we documented robust positive associations of the plasma
434 omega-6/omega-3 fatty acids ratio with the risk of all-cause, cancer, and CVD mortality.
435 Moreover, we found that plasma omega-3 and omega-6 PUFAs were independently and
436 inversely associated with the three mortality outcomes, with omega-3 fatty acids showing
437 stronger protective effects. Our findings support the active management of a high circulating
438 level of omega-3 fatty acids and a low omega-6/omega-3 ratio to prevent premature death.

439

440 **Declarations**

441 **Ethics approval and consent to participate**

442 The UK Biobank received ethical approval from the research ethics committee (reference ID: 11/
443 NW/0382). Written informed consent was obtained from participants.

444 **Consent for publication**

445 Not applicable.

446 **Availability of data and materials**

447 The datasets analyzed during the current study are available from the UK Biobank through an
448 application process (www.ukbiobank.ac.uk/).

449 **Competing interests**

450 The authors declare no competing interests.

451 **Funding**

452 Research reported in this publication was supported by the National Institute of General Medical
453 Sciences of the National Institute of Health under the award number R35GM143060 (KY). The
454 content is solely the responsibility of the authors and does not necessarily represent the official
455 views of the National Institutes of Health.

456 **Authors' contributions**

457 YZ performed data analysis, prepared visualizations, and wrote the original draft of the
458 manuscript. YS, YQ, and SS contributed to the data analysis. YS (yeshen@uga.edu) and KY
459 (kaixiong.ye@uga.edu) contributed equally to this project and should be considered co-
460 corresponding authors. They jointly designed and supervised the project. JTB contributed to the
461 interpretations of results. All authors critically edited the manuscript for important intellectual
462 content. The corresponding author (KY) attests that all listed authors meet the authorship criteria
463 and that no others meeting the criteria were omitted.

464 **Acknowledgements**

465 This research has been conducted using the UK Biobank Resource under Application Number
466 48818. We would like to express our heartfelt gratitude to the UK Biobank participants and
467 administrative staff.

468

469

470

471

472

473 **Abbreviations**

95% CI	95% confidence interval
ANOVA	Analysis of variance
ApoA	Apolipoprotein A
ApoB	Apolipoprotein B
BMI	Body mass index
CRP	C-creative protein
CVD	Cardiovascular disease
DHA	Docosahexaenoic acid
DHA%	Docosahexaenoic acid to total fatty acids percentage
E2	Oestradiol
EPA	Eicosapentaenoic acid
HDL-C	High density lipoprotein-cholesterol
HR	Hazard ratio
LA	Linoleic acid
LA%	Linoleic acid to total fatty acids percentage
IGF-1	Insulin-like growth factor 1
LDL	Low density lipoprotein
Lp(a)	Lipoprotein A
Omega-3%	Omega-3 fatty acids to total fatty acids percentage
Omega-6%	Omega-6 fatty acids to total fatty acids percentage
PUFAs	Polyunsaturated fatty acids
Ref	Reference
SD	Standard deviation
SHBG	Sex hormone binding globulin
TG	Triglyceride
TTST	Testosterone

474

475

476

477

478

479 **Supplementary Information**

480 **Additional file 1: Table S1.** Literature review.

481 **Additional file 2: Table S2.** Risk estimates of ratio of plasma omega-6 to omega-3 PUFAs with

482 all-cause, cancer and CVD mortality, stratified by potential risk factors, in the UK Biobank

483 Study. **Table S3.** Associations of plasma omega-3 PUFAs percentage with all-cause, cancer, and

484 CVD mortality risk in the UK Biobank Study. **Table S4.** Associations of plasma omega-6

485 PUFAs percentage with all-cause, cancer, and CVD mortality risk in the UK Biobank Study.

486 **Table S5.** Fully adjusted joint associations of plasma omega-3 PUFAs percentage and omega-6

487 PUFAs percentage with all-cause and cause-specific mortality in the UK Biobank Study. **Table**

488 **S6.** Associations of the dietary PUFAs with all-cause, cancer, and CVD mortality risk in the UK

489 Biobank. **Table S7.** Selected participants serum biochemical markers at baseline across quintiles

490 of the plasma omega-6/omega-3 PUFAs ratio. **Table S8.** Mediation analysis of biomarkers on

491 associations between plasma omega-6/omega-3 ratio and mortality. **Figure S1.** Directed acyclic

492 graph to explain mediation. **Table S9.** Associations of DHA and LA with all-cause, cancer, and

493 CVD mortality risk in the UK Biobank. **Table S10.** Associations of ratio of omega-6/omega-3

494 PUFAs with all-cause, cancer, and CVD mortality risk in the UK Biobank, covariates including

495 fish oil supplementation status. **Table S11.** Associations of ratio of omega-6/omega-3 PUFAs
496 with all-cause, cancer, and CVD mortality risk in the UK Biobank Study, with multiple
497 imputation for missing data. **Table S12.** Associations of ratio of omega-6/omega-3 PUFAs with
498 all-cause, cancer, and CVD mortality risk in the UK Biobank Study, excluding those who died in
499 the first follow-up year. **Table S13.** Baseline characteristics of participants with missing
500 exposure information and not included in the study.

501

502 **References**

- 503 1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries
504 and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
505 2019. *Lancet*. 2020;396(10258):1204-1222.
- 506 2. Harris WS. The omega-3 index: from biomarker to risk marker to risk factor. *Curr Atheroscler*
507 *Rep*. 2009;11(6):411-417.
- 508 3. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary
509 heart disease? *Prev Med*. 2004;39(1):212-220.
- 510 4. Harris WS, Luo J, Pottala JV, et al. Red blood cell polyunsaturated fatty acids and mortality
511 in the Women's Health Initiative Memory Study. *J Clin Lipidol*. 2017;11(1):250-259.e255.
- 512 5. Harris WS, Tintle NL, Etherton MR, Vasan RS. Erythrocyte long-chain omega-3 fatty acid
513 levels are inversely associated with mortality and with incident cardiovascular disease: The
514 Framingham Heart Study. *J Clin Lipidol*. 2018;12(3):718-727.e716.
- 515 6. Kleber ME, Delgado GE, Lorkowski S, März W, von Schacky C. Omega-3 fatty acids and
516 mortality in patients referred for coronary angiography. The Ludwigshafen Risk and
517 Cardiovascular Health Study. *Atherosclerosis*. 2016;252:175-181.
- 518 7. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for
519 Hypertriglyceridemia. *N Engl J Med*. 2019;380(1):11-22.
- 520 8. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil
521 on major adverse cardiovascular events in patients at high cardiovascular risk: the
522 STRENGTH randomized clinical trial. *JAMA*. 2020;324(22):2268-2280.
- 523 9. Delgado GE, März W, Lorkowski S, von Schacky C, Kleber ME. Omega-6 fatty acids:
524 opposing associations with risk-The Ludwigshafen Risk and Cardiovascular Health Study. *J*
525 *Clin Lipidol*. 2017;11(4):1082-1090.e1014.
- 526 10. Marklund M, Wu JHY, Imamura F, et al. Biomarkers of dietary omega-6 fatty acids and
527 incident cardiovascular disease and mortality. *Circulation*. 2019;139(21):2422-2436.
- 528 11. Wu JHY, Lemaitre RN, King IB, et al. Circulating omega-6 polyunsaturated fatty acids and
529 total and cause-specific mortality. *Circulation*. 2014;130(15):1245-1253.

- 530 12. Harris K, Oshima M, Sattar N, et al. Plasma fatty acids and the risk of vascular disease and
531 mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study.
532 *Diabetologia*. 2020;63(8):1637-1647.
- 533 13. Miura K, Hughes MCB, Ungerer JPJ, Green AC. Plasma eicosapentaenoic acid is negatively
534 associated with all-cause mortality among men and women in a population-based
535 prospective study. *Nutr Res*. 2016;36(11):1202-1209.
- 536 14. Otsuka R, Tange C, Nishita Y, et al. Fish and meat intake, serum eicosapentaenoic acid and
537 docosahexaenoic acid levels, and mortality in community-dwelling Japanese older persons.
538 *Int J Environ Res Public Health*. 2019;16(10).
- 539 15. Zhuang P, Wang W, Wang J, Zhang Y, Jiao J. Polyunsaturated fatty acids intake, omega-
540 6/omega-3 ratio and mortality: Findings from two independent nationwide cohorts. *Clin Nutr*.
541 2019;38(2):848-855.
- 542 16. Shim JS, Oh K, Kim HC. Dietary assessment methods in epidemiologic studies. *Epidemiol*
543 *Health*. 2014;36:e2014009.
- 544 17. Simopoulos AP. Evolutionary aspects of diet and essential fatty acids. *World Rev Nutr Diet*.
545 2001;88:18-27.
- 546 18. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular
547 disease and other chronic diseases. *Exp Biol Med*. 2008;233(6):674-688.
- 548 19. Noori N, Dukkupati R, Kovesdy CP, et al. Dietary omega-3 fatty acid, ratio of omega-6 to
549 omega-3 intake, inflammation, and survival in long-term hemodialysis patients. *Am J of*
550 *Kidney Dis*. 2011;58(2):248-256.
- 551 20. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying
552 the causes of a wide range of complex diseases of middle and old age. *PLOS Med*.
553 2015;12(3):e1001779.
- 554 21. Julkunen H, Cichońska A, Slagboom PE, Würtz P, Nightingale Health UKBI. Metabolic
555 biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in
556 the general population. *eLife*. 2021;10:e63033.
- 557 22. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative
558 serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -
559 Omic technologies. *Am J Epidemiol*. 2017;186(9):1084-1096.
- 560 23. Perez-Cornago A, Pollard Z, Young H, et al. Description of the updated nutrition calculation
561 of the Oxford WebQ questionnaire and comparison with the previous version among 207,144
562 participants in UK Biobank. *Eur J Nutr*. 2021;60(7):4019-4030.
- 563 24. Chua ME, Sio MC, Sorongon MC, Dy JS. Relationship of dietary intake of omega-3 and
564 omega-6 Fatty acids with risk of prostate cancer development: a meta-analysis of
565 prospective studies and review of literature. *Prostate Cancer*. 2012;2012:826254.
- 566 25. Durrleman S, Simon R. Flexible regression models with cubic splines. *Stat Med*.
567 1989;8(5):551-561.
- 568 26. Li Z-H, Zhong W-F, Liu S, et al. Associations of habitual fish oil supplementation with
569 cardiovascular outcomes and all cause mortality: evidence from a large population based
570 cohort study. *BMJ*. 2020;368:m456.
- 571 27. Zhang Y, Zhuang P, He W, et al. Association of fish and long-chain omega-3 fatty acids
572 intakes with total and cause-specific mortality: prospective analysis of 421 309 individuals. *J*
573 *Intern Med*. 2018;284(4):399-417.

- 574 28. Lapointe-Shaw L, Bouck Z, Howell NA, et al. Mediation analysis with a time-to-event
575 outcome: a review of use and reporting in healthcare research. *BMC Medical Research*
576 *Methodology*. 2018;18(1):118.
- 577 29. Valeri L, VanderWeele TJ. SAS Macro for Causal Mediation Analysis with Survival Data.
578 *Epidemiology*. 2015;26(2):e23-e24.
- 579 30. VanderWeele TJ. Causal mediation analysis with survival data. *Epidemiology*.
580 2011;22(4):582-585.
- 581 31. van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations
582 in R. *J Stat Softw*. 2011;45(3):1 - 67.
- 583 32. Murff HJ, Tindle HA, Shrubsole MJ, et al. Smoking and red blood cell phospholipid
584 membrane fatty acids. *Prostaglandins Leukot Essent Fatty Acids*. 2016;112:24-31.
- 585 33. Scaglia N, Chatkin J, Chapman KR, et al. The relationship between omega-3 and smoking
586 habit: a cross-sectional study. *Lipids Health Dis*. 2016;15:61.
- 587 34. Chen GC, Yang J, Eggersdorfer M, Zhang W, Qin LQ. N-3 long-chain polyunsaturated fatty
588 acids and risk of all-cause mortality among general populations: a meta-analysis. *Sci Rep*.
589 2016;6:28165.
- 590 35. Eide IA, Dahle DO, Svensson M, et al. Plasma levels of marine n-3 fatty acids and
591 cardiovascular risk markers in renal transplant recipients. *Eur J Clin Nutr*. 2016;70(7):824-
592 830.
- 593 36. Harris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and total and cause-
594 specific mortality from 17 prospective studies. *Nat Commun*. 2021;12(1):2329.
- 595 37. Lee S-H, Shin M-J, Kim J-S, et al. Blood eicosapentaenoic acid and docosahexaenoic acid
596 as predictors of all-cause mortality in patients with acute myocardial infarction-data from
597 Infarction Prognosis Study (IPS) Registry. *Circ J*. 2009;73(12):2250-2257.
- 598 38. Lindberg M, Saltvedt I, Sletvold O, Bjerve KS. Long-chain n-3 fatty acids and mortality in
599 elderly patients. *Am J Clin Nutr*. 2008;88(3):722-729.
- 600 39. Pertiwi K, Küpers LK, Goede Jd, Zock PL, Kromhout D, Geleijnse JM. Dietary and circulating
601 long-chain omega-3 polyunsaturated fatty acids and mortality risk after myocardial infarction:
602 a long-term follow-up of the Alpha Omega Cohort. *J Am Heart Assoc*. 2021;10(23):e022617.
- 603 40. Pottala JV, Garg S, Cohen BE, Whooley MA, Harris WS. Blood eicosapentaenoic and
604 docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart
605 disease: the Heart and Soul study. *Circ Cardiovasc Qual Outcomes*. 2010;3(4):406-412.
- 606 41. Miura K, Hughes MCB, Ungerer JPJ, Smith DD, Green AC. Absolute versus relative
607 measures of plasma fatty acids and health outcomes: example of phospholipid omega-3 and
608 omega-6 fatty acids and all-cause mortality in women. *Eur J Nutr*. 2018;57(2):713-722.
- 609 42. Warensjö E, Sundström J, Vessby B, Cederholm T, Risérus U. Markers of dietary fat quality
610 and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-
611 based prospective study. *Am J Clin Nutr*. 2008;88(1):203-209.
- 612 43. de Lorgeril M, Renaud S, Salen P, et al. Mediterranean alpha-linolenic acid-rich diet in
613 secondary prevention of coronary heart disease. *Lancet*. 1994;343(8911):1454-1459.
- 614 44. Petrone AB, Weir N, Hanson NQ, et al. Omega-6 fatty acids and risk of heart failure in the
615 Physicians' Health Study. *Am J Clin Nutr*. 2012;97(1):66-71.
- 616 45. Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Akabane M, Tsugane S. Single
617 measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake in
618 middle-aged Japanese men. *Eur J Clin Nutr*. 2001;55(8):643-650.

- 619 46. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to
620 regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol.*
621 1999;150(4):341-353.

Tables

Table 1. Selected participants characteristics at baseline across quintiles of the plasma omega-6/omega-3 PUFAs ratio (n=85,425).

Characteristics ^a	Omega-6/omega-3 ratio quintiles					P
	1 (median = 5.9) (n = 17,085)	2 (median = 7.6) (n = 17,085)	3 (median = 9.1) (n = 17,085)	4 (median = 11.0) (n = 17,085)	5 (median = 14.8) (n = 17,085)	
Age (years)	58.6 (7.5)	57.2 (7.9)	55.7 (8.2)	54.7 (8.3)	53.4 (8.2)	<0.001 ^b
Sex (male%)	40.3	44.9	47.5	49.4	52.8	<0.001 ^c
Ethnicity (n%)						
White	15,375 (90.4%)	15,486 (91.0%)	15,494 (91.1%)	15,467 (91.1%)	15,420 (90.7%)	0.384 ^c
Black	113 (0.7%)	99 (0.6%)	105 (0.6%)	92 (0.5%)	116 (0.7%)	
Asian	673 (4.0%)	639 (3.8%)	663 (3.9%)	653 (3.8%)	659 (3.9%)	
Others	844 (5.0%)	786 (4.6%)	742 (4.4%)	773 (4.6%)	810 (4.8%)	
Missing (n)	80	75	81	100	80	
BMI	27.0 (4.4)	27.3 (4.5)	27.3 (4.7)	27.3 (4.8)	26.9 (5.0)	<0.001 ^b
Missing (n)	54	64	55	58	71	
TDI	-1.6 (3.0)	-1.5 (3.0)	-1.4 (3.1)	-1.2 (3.1)	-0.9 (3.2)	<0.001 ^b
Missing (n)	17	24	24	28	22	
Smoking status (n%)						<0.001 ^c
Never	9,426 (55.5%)	9,272 (54.6%)	9,424 (55.4%)	9,400 (55.3%)	9,214 (54.2%)	
Previous	6,402 (37.7%)	6,194 (36.5%)	5,772 (34.0%)	5,492 (32.3%)	4,951 (29.1%)	
Current	1,162 (6.8%)	1,526 (9.0%)	1,802 (10.6%)	2,104 (12.4%)	2,832 (16.7%)	
Missing (n)	95	93	87	89	88	
Alcohol status (n%)						<0.001 ^c
Never	631 (3.7%)	676 (4.0%)	655 (3.8%)	755 (4.4%)	974 (5.7%)	
Previous	536 (3.1%)	554 (3.2%)	535 (3.1%)	617 (3.6%)	835 (4.9%)	
Current	15,877 (93.2%)	15,822 (92.8%)	15,847 (93.0%)	15,664 (91.9%)	15,221 (89.4%)	
Missing (n)	41	33	48	49	55	
Physical activity (n%)						<0.001 ^c
Low	2,422 (17.4%)	2,602 (18.8%)	2,653 (19.1%)	2,617 (19.0%)	2,613 (18.9%)	
Moderate	5,879 (42.2%)	5,762 (41.5%)	5,712 (41.1%)	5,533 (40.1%)	5,327 (38.6%)	
High	5,635 (40.4%)	5,506 (39.7%)	5,545 (39.9%)	5,654 (41.0%)	5,854 (42.4%)	
Missing (n)	3,149	3,215	3,175	3,281	3,291	

Fish oil supplementation (Yes%)	48.1	37.7	29.6	22.7	15.5	<0.001 ^c
<i>Missing (n)</i>	50	47	77	82	71	
Comorbidity (Yes%)	38.6	37.3	34.2	33.8	33.0	<0.001 ^c
Plasma omega-3 percentage	6.6 (1.4)	4.9 (0.5)	4.2 (0.4)	3.5 (0.3)	2.6 (0.5)	<0.001 ^b
Plasma omega-6 percentage	36.3 (3.7)	37.4 (3.4)	38.2 (3.3)	39.1 (3.2)	40.2 (3.1)	<0.001 ^b
Plasma DHA percentage	2.8 (0.8)	2.1 (0.5)	1.9 (0.4)	1.7 (0.4)	1.5 (0.4)	<0.001 ^b
Plasma LA percentage	27.0 (3.3)	28.4 (3.1)	29.3 (3.0)	30.2 (3.0)	31.3 (3.1)	<0.001 ^b
Dietary omega-3 percentage	3.6 (1.8)	3.2 (1.4)	3.0 (1.3)	2.9 (1.2)	2.7 (1.0)	<0.001 ^b
<i>Missing (n)</i>	9,355	9,628	9,857	9,974	10,288	
Dietary omega-6 percentage	16.8 (4.6)	16.5 (4.4)	16.6 (4.6)	16.5 (4.7)	16.5 (4.8)	<0.001 ^b
<i>Missing (n)</i>	9,355	9,628	9,857	9,974	10,288	

^a All variables measured at baseline are presented as mean (SD) unless otherwise specified.

^b From the ANOVA test for continuous variables.

^c From the Pearson's Chi-squared test for categorical variables.

Table 2. Associations^a of the plasma omega-6/omega-3 PUFAs ratio with all-cause, cancer, and CVD mortality risk in the UK Biobank.

Omega ratio variable forms	Causes of death								
	All-cause			Cancer			Cardiovascular diseases		
	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c
		HR (95% CI)	HR (95% CI)		HR (95% CI)	HR (95% CI)		HR (95% CI)	HR (95% CI)
Continuous	6,461	1.02 (1.02-1.03)	1.02 (1.02-1.03)	2,794	1.02 (1.01-1.03)	1.01 (1.00-1.02)	1,668	1.02 (1.01-1.03)	1.02 (1.01-1.03)
Quintiles (median)									
1 (5.9)	1,348	1.00 (ref)	1.00 (ref)	593	1.00 (ref)	1.00 (ref)	369	1.00 (ref)	1.00 (ref)
2 (7.6)	1,256	1.00 (0.92-1.08)	0.96 (0.88-1.05)	563	1.02 (0.91-1.15)	0.98 (0.86-1.12)	315	0.90 (0.77-1.05)	0.89 (0.75-1.06)
3 (9.1)	1,236	1.06 (0.98-1.15)	1.01 (0.93-1.11)	543	1.08 (0.96-1.21)	0.99 (0.87-1.13)	321	0.97 (0.84-1.13)	0.97 (0.81-1.16)
4 (11.0)	1,252	1.14 (1.06-1.23)	1.09 (1.00-1.19)	548	1.16 (1.03-1.31)	1.12 (0.98-1.27)	306	0.98 (0.84-1.15)	1.02 (0.86-1.22)
5 (14.8)	1,369	1.34 (1.24-1.45)	1.26 (1.15-1.38)	547	1.27 (1.12-1.43)	1.14 (1.00-1.31)	357	1.20 (1.04-1.40)	1.31 (1.10-1.55)
<i>P</i> _{trend}		<0.001	<0.001		<0.001	0.011		0.002	<0.001

Abbreviations: CI, confidence interval; HR, hazards ratio; ref, reference.

^a From Cox proportional hazards regression.

^b Adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre.


^c Adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure Legends

Figure 1. Risk estimates of all-cause mortality for the highest compared with the lowest quintile of the ratio of plasma omega-6 to omega-3 PUFAs, stratified by potential risk factors. Results were adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure 2. Risk estimates of cause-specific mortality for the highest compared with the lowest quintile of the ratio of plasma omega-6 to omega-3 PUFAs, stratified by potential risk factors. Results were adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure 3. Associations of the ratio of omega-6/omega-3 PUFAs with all-cause and cause-specific mortality evaluated using restricted cubic splines. Hazard ratios and omega ratios are presented in the vertical and horizontal axis, respectively. The best estimates and their confidence intervals are presented as solid red lines and dotted black lines, respectively. The ratio 4 was selected as a reference level, and the x-axis depicts the ratio from 0 to 40. Potential nonlinearity was identified for all-cause mortality ($p < 0.05$) and CVD-caused mortality ($p < 0.05$), but not for cancer-caused mortality ($p = 0.12$). All HRs are adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).




Cancer Mortality

CVD Mortality


Subgroup	No. of Participants	No. of Death (%)	Cancer Mortality		CVD Mortality		
			Hazard Ratio (95% CI)	P value for interaction	Hazard Ratio (95% CI)	P value for interaction	
Overall	17,085	547 (3.2)	1.14 (1.00-1.31)		357 (2.09)	1.31 (1.10-1.55)	
Age (years)				0.85			0.56
< 58	11,146	188 (1.69)	1.07 (0.80-1.43)		112 (1)	1.11 (0.77-1.61)	
>= 58	5,939	359 (6.04)	1.04 (0.89-1.21)		245 (4.13)	1.24 (1.02-1.51)	
Sex				0.33			0.73
Male	9,020	355 (3.94)	1.17 (0.98-1.40)		282 (3.13)	1.31 (1.08-1.60)	
Female	8,065	192 (2.38)	1.11 (0.89-1.38)		75 (0.93)	1.31 (0.91-1.88)	
TDI				0.4			0.87
< -2	7,823	240 (3.07)	1.06 (0.88-1.28)		121 (1.55)	1.35 (1.04-1.75)	
>= -2	9,240	307 (3.32)	1.29 (1.06-1.58)		235 (2.54)	1.32 (1.05-1.66)	
BMI (kg/m ²)				0.78			0.62
< 25	6,673	184 (2.76)	1.04 (0.81-1.34)		97 (1.45)	1.32 (0.93-1.88)	
>= 25	10,341	362 (3.5)	1.19 (1.01-1.40)		257 (2.49)	1.30 (1.07-1.59)	
Comorbidity				0.74			<0.001
Yes	5,639	282 (5)	1.12 (0.93-1.35)		250 (4.43)	1.24 (1.01-1.52)	
No	11,446	265 (2.32)	1.17 (0.96-1.43)		107 (0.93)	1.47 (1.05-2.06)	
Physical Activity				0.99			0.16
Low or Moderate	7,940	247 (3.11)	1.17 (0.98-1.39)		180 (2.27)	1.37 (1.10-1.70)	
High	5,854	165 (2.82)	1.11 (0.89-1.38)		100 (1.71)	1.22 (0.91-1.62)	
Current Smoking Status				0.13			0.12
Yes	2,832	176 (6.21)	1.41 (1.01-1.97)		116 (4.1)	2.09 (1.33-3.27)	
No	14,165	367 (2.59)	1.06 (0.91-1.23)		238 (1.68)	1.18 (0.97-1.43)	

i: https://doi.org/10.1101/2023.01.16.23284631; this version posted June 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.


All-cause Mortality



Cancer Mortality



CVD Mortality



esueciji jenoitay eulj 6 7 CN 18 20 g. repun eipelle/ve epew si tl
Eupreio to sed om aly (18) 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
"L1 eunn peisod uoisex sui : 15968282791 : 10'820Z/10111'01/0100//sdiu
aut leidsip ot esueciji e aixRpeu peisod uoisex sui : 15968282791 : 10'820Z/10111'01/0100//sdiu
6biu/Adoc eu 1 : 820Z '21 eunn peisod uoisex sui : 15968282791 : 10'820Z/10111'01/0100//sdiu